Mr. Larry Rogers reports

ORGANIGRAM HOLDINGS ANNOUNCES $35 MILLION BOUGHT DEAL

Organigram Holdings Inc. has entered into a letter of engagement with Dundee Securities Ltd. on behalf of a syndicate of underwriters under which the underwriters have agreed to purchase 9.86 million common shares of the company on a bought deal basis pursuant to the filing of a short form prospectus, subject to all required regulatory approvals, at a price per share of $3.55, for total gross proceeds of $35,003,000.

The company has agreed to grant the underwriters an overallotment option to purchase up to an additional 1,479,000 shares at the offering at the offering price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the offering. If this option is exercised in full, an additional $5,250,450 will be raised pursuant to the offering, and the aggregate proceeds of the offering will be $40,253,450.

The company intends to use the net proceeds of the offering for capital expenditures, and for working capital and general corporate purposes.

The shares will be offered by way of a short form prospectus to be filed in all of the provinces of Canada, excluding Quebec, pursuant to National Instrument 44-101, short form prospectus distributions.

The closing date of the offering is scheduled to be on or about Dec. 7, 2016, and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the TSX Venture Exchange and the applicable securities regulatory authorities.

About Organigram Holdings

Organigram Holdings' wholly owned subsidiary, Organigram Inc., is a licensed producer of medical marijuana in Canada.

We seek Safe Harbor.